<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Sciences : Microbiology : Medical Microbiology : Microbial Pathogens :" exact="Viral" post="Pathogens : Flaviviruses: Zika Virus : Medicine and Health"/>
 <result pre="Pathology and Laboratory Medicine : Pathogens : Microbial Pathogens :" exact="Viral" post="Pathogens : Flaviviruses: Zika Virus : Biology and Life"/>
 <result pre=": Biology and Life Sciences : Organisms : Viruses :" exact="Viral" post="Pathogens : Flaviviruses: Zika Virus : Biology and life"/>
 <result pre=": Cell Biology : Cellular Types : Animal Cells :" exact="Blood" post="Cells : White Blood Cells: T Cells : Biology"/>
 <result pre="Cellular Types : Animal Cells : Blood Cells : White" exact="Blood" post="Cells: T Cells : Biology and Life Sciences :"/>
 <result pre="Cellular Types : Animal Cells : Immune Cells : White" exact="Blood" post="Cells: T Cells : Biology and Life Sciences :"/>
 <result pre="and Life Sciences : Immunology : Immune Cells : White" exact="Blood" post="Cells: T Cells : Medicine and Health Sciences :"/>
 <result pre="and Health Sciences : Immunology : Immune Cells : White" exact="Blood" post="Cells: T Cells : Biology and Life Sciences :"/>
 <result pre=": Immunology: Immune Response : Medicine and Health Sciences :" exact="Infectious" post="Diseases : Viral Diseases: Viremia : Research and Analysis"/>
 <result pre="Immunology: Immune Response : Medicine and Health Sciences : Infectious" exact="Diseases" post=": Viral Diseases: Viremia : Research and Analysis Methods"/>
 <result pre="Response : Medicine and Health Sciences : Infectious Diseases :" exact="Viral" post="Diseases: Viremia : Research and Analysis Methods : Animal"/>
 <result pre=": Cell biology : Cellular types : Animal cells :" exact="Blood" post="cells : White blood cells : T cells: Cytotoxic"/>
 <result pre="Proteins: Antibodies Effective control of early Zika virus replication by" exact="Dengue" post="immunity is associated to the length of time between"/>
 <result pre="is associated to the length of time between the 2" exact="infections" post="but not mediated by antibodies Time, a critical factor"/>
 <result pre="antibodies Time, a critical factor to control Zika replication by" exact="Dengue" post="immunity Serrano-CollazoCrisantaConceptualizationFormal analysisInvestigationMethodologySupervisionValidationWriting – original draftWriting – review &amp;amp;"/>
 <result pre="antibodies (Abs) or the cellular immune response generated by a" exact="primary" post="dengue (DENV) infection on the course of a secondary"/>
 <result pre="the cellular immune response generated by a primary dengue (DENV)" exact="infection" post="on the course of a secondary zika (ZIKV) infection"/>
 <result pre="a primary dengue (DENV) infection on the course of a" exact="secondary" post="zika (ZIKV) infection in vivo. Here we show that"/>
 <result pre="(DENV) infection on the course of a secondary zika (ZIKV)" exact="infection" post="in vivo. Here we show that the length of"/>
 <result pre="Here we show that the length of time between DENV/ZIKV" exact="infections" post="has a qualitative impact on controlling early ZIKV replication."/>
 <result pre="and durability of the neutralizing antibodies (nAbs) induced by a" exact="secondary" post="ZIKV infection is modest compared to the response induced"/>
 <result pre="of the neutralizing antibodies (nAbs) induced by a secondary ZIKV" exact="infection" post="is modest compared to the response induced after a"/>
 <result pre="infection is modest compared to the response induced after a" exact="secondary" post="heterologous DENV infection. Our in vivo results are showing"/>
 <result pre="dependent. Taken together, our results suggest that early after ZIKV" exact="infection" post="other mechanisms such as the innate and cellular immune"/>
 <result pre="in controlling ZIKV replication. Regardless of the time elapsed between" exact="infections" post="there was no evidence of in vivo antibody-dependent enhancement"/>
 <result pre="questions remain unanswered. One is precisely if the time between" exact="primary" post="DENV and a subsequent ZIKV infections may play a"/>
 <result pre="if the time between primary DENV and a subsequent ZIKV" exact="infections" post="may play a role in the degree of protection"/>
 <result pre="that a period of 12 months between DENV and ZIKV" exact="infections" post="has a significant impact controlling ZIKV replication compared to"/>
 <result pre="Health P51 OD011133Luis D Giavedoni http://dx.doi.org/10.13039/100000060National Institute of Allergy and" exact="Infectious" post="Diseases K22AI104794BrienJames D This work received support by Grants"/>
 <result pre="P51 OD011133Luis D Giavedoni http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious" exact="Diseases" post="K22AI104794BrienJames D This work received support by Grants 2"/>
 <result pre="and CAS (ORIP, OD, NIH), and R25GM061838 to C.S.-C. Also," exact="partial" post="support was provided by Grant K22AI104794 to JDB (NIAID)"/>
 <result pre="to unique severe adverse outcomes such as fetal loss [1]," exact="congenital" post="Zika syndrome (CZS) [2], Guillain-Barré syndrome (GBS) [3], and"/>
 <result pre="severe adverse outcomes such as fetal loss [1], congenital Zika" exact="syndrome" post="(CZS) [2], Guillain-Barré syndrome (GBS) [3], and rare cases"/>
 <result pre="such as fetal loss [1], congenital Zika syndrome (CZS) [2]," exact="Guillain-Barré syndrome" post="(GBS) [3], and rare cases of encephalopathy [4], meningoencephalitis"/>
 <result pre="as fetal loss [1], congenital Zika syndrome (CZS) [2], Guillain-Barré" exact="syndrome" post="(GBS) [3], and rare cases of encephalopathy [4], meningoencephalitis"/>
 <result pre="(CZS) [2], Guillain-Barré syndrome (GBS) [3], and rare cases of" exact="encephalopathy" post="[4], meningoencephalitis [5], myelitis [6], uveitis [7], and severe"/>
 <result pre="Guillain-Barré syndrome (GBS) [3], and rare cases of encephalopathy [4]," exact="meningoencephalitis" post="[5], myelitis [6], uveitis [7], and severe thrombocytopenia [8]."/>
 <result pre="(GBS) [3], and rare cases of encephalopathy [4], meningoencephalitis [5]," exact="myelitis" post="[6], uveitis [7], and severe thrombocytopenia [8]. ZIKV is"/>
 <result pre="and rare cases of encephalopathy [4], meningoencephalitis [5], myelitis [6]," exact="uveitis" post="[7], and severe thrombocytopenia [8]. ZIKV is mainly transmitted"/>
 <result pre="encephalopathy [4], meningoencephalitis [5], myelitis [6], uveitis [7], and severe" exact="thrombocytopenia" post="[8]. ZIKV is mainly transmitted through the bite of"/>
 <result pre="of Aedes aegypti, the same vector implicated in dengue (DENV)" exact="infection" post="but there are however other routes of infection including"/>
 <result pre="dengue (DENV) infection but there are however other routes of" exact="infection" post="including sexual contact [9–11] and vertical transmission [12–14] that"/>
 <result pre="exposure to a single DENV serotype predisposes individuals to severe" exact="disease" post="upon a secondary heterologous DENV infection, and the time"/>
 <result pre="single DENV serotype predisposes individuals to severe disease upon a" exact="secondary" post="heterologous DENV infection, and the time interval between infections"/>
 <result pre="a secondary heterologous DENV infection, and the time interval between" exact="infections" post="has been considered as a risk factor [17]. A"/>
 <result pre="infections has been considered as a risk factor [17]. A" exact="short" post="interval of time between homologous or heterologous DENV infections"/>
 <result pre="A short interval of time between homologous or heterologous DENV" exact="infections" post="usually results in protection from disease, while an extended"/>
 <result pre="extended period of time is associated with the potential for" exact="severe dengue" post="[18–20], due to either cross-reactive non-neutralizing antibodies (Abs) [21,"/>
 <result pre="association of previous flavivirus exposure at any time before ZIKV" exact="infection" post="with the severe adverse outcomes of the infection is"/>
 <result pre="before ZIKV infection with the severe adverse outcomes of the" exact="infection" post="is still unclear. Previously, we showed that a primary"/>
 <result pre="the infection is still unclear. Previously, we showed that a" exact="primary" post="DENV infection (&amp;gt;2 years) does not result in an"/>
 <result pre="is still unclear. Previously, we showed that a primary DENV" exact="infection" post="(&amp;gt;2 years) does not result in an increase in"/>
 <result pre="in DENV-experimented individuals may play a key role limiting ZIKV" exact="infection" post="[26]. Our results on the potential protective role of"/>
 <result pre="on the potential protective role of pre-existing DENV-immunity against ZIKV" exact="infection" post="were validated by subsequent NHP works [27, 28] and"/>
 <result pre="behind DENV and ZIKV interactions. It has been shown that" exact="primary" post="DENV infections do not induce durable ZIKV cross-neutralizing Abs"/>
 <result pre="and ZIKV interactions. It has been shown that primary DENV" exact="infections" post="do not induce durable ZIKV cross-neutralizing Abs [31, 32]"/>
 <result pre="to human cohorts is that they allow the control of" exact="external" post="factors, such as the exact moment of infection and"/>
 <result pre="control of external factors, such as the exact moment of" exact="infection" post="and the amount of the administered viral inoculum [33]."/>
 <result pre="exact moment of infection and the amount of the administered" exact="viral" post="inoculum [33]. Furthermore, the similarity of their competent immune"/>
 <result pre="system with humans is critical for understanding the mechanisms behind" exact="disease" post="pathogenesis. By using rhesus macaques with primary DENV infections"/>
 <result pre="the mechanisms behind disease pathogenesis. By using rhesus macaques with" exact="primary" post="DENV infections at two different points of time, followed"/>
 <result pre="behind disease pathogenesis. By using rhesus macaques with primary DENV" exact="infections" post="at two different points of time, followed by a"/>
 <result pre="infections at two different points of time, followed by a" exact="secondary" post="ZIKV infection, we found that the length of time"/>
 <result pre="infection, we found that the length of time separating the" exact="infections" post="has a qualitative impact on controlling ZIKV replication. It"/>
 <result pre="the extent of the contribution of DENV-Abs early after ZIKV" exact="infection" post="in vivo remains uncertain. For this reason, we looked"/>
 <result pre="time of at least 12 months between DENV and ZIKV" exact="infections" post="results in a significant increase in the frequency of"/>
 <result pre="dendritic plasmacytoid cells (pDCs) in the first days after ZIKV" exact="infection" post="and with a trend to higher frequency of interferon"/>
 <result pre="cells. Taken together, these data suggest that early after ZIKV" exact="infection" post="the cellular immune response, and not Abs, may play"/>
 <result pre="ZIKV PRVABC59 on the same day, defining exposure time between" exact="infections" post="for cohorts 1 and 2 as 12 months or"/>
 <result pre="San Juan, Puerto Rico. Fig 1 Experimental design of ZIKV" exact="infection" post="in DENV-immune and naïve macaques. Two cohorts of rhesus"/>
 <result pre="of ZIKV and DENV naïve animals (n = 6). ZIKV" exact="infection" post="was performed 12 months after DENV infection for cohort"/>
 <result pre="= 6). ZIKV infection was performed 12 months after DENV" exact="infection" post="for cohort 1 (n = 6), and 3 months"/>
 <result pre="cohort 1 (n = 6), and 3 months after DENV" exact="infection" post="for cohort 2 (n = 4). Serum was collected"/>
 <result pre="collected at baseline and days 1 through 7 post ZIKV" exact="infection" post="(p.i.). Sample collection was interrupted by Hurricane María’s impact,"/>
 <result pre="status and laboratory results To determine how a previous DENV" exact="infection" post="affects the clinical status of non-human primates after infection"/>
 <result pre="DENV infection affects the clinical status of non-human primates after" exact="infection" post="with ZIKV, day 0 (baseline), day 6 p.i. and"/>
 <result pre="p.i. and day 30 p.i. were compared in terms of" exact="complete" post="blood count. All sixteen animals belonging to this study"/>
 <result pre="were continuously monitored and evaluated twice daily for evidence of" exact="disease" post="or injury. All animals were inside the range in"/>
 <result pre="and urine using qRT-PCR. During the first 3 days p.i.," exact="viral" post="RNA detection increased similarly in all groups (Fig 2A)."/>
 <result pre="groups (Fig 2A). Of note, DENV-middle convalescent animals had significantly" exact="lower" post="peak viremia on day 4 p.i. compared with the"/>
 <result pre="in the four animals from DENV 12M group was significantly" exact="lower" post="compared to the four animals having viremia in the"/>
 <result pre="1). By days 6 and 7 p.i., there was no" exact="viral" post="RNA detection in the DENV-middle convalescent group, while DENV"/>
 <result pre="viremia and most of the naïve animals still had detectable" exact="viral" post="RNA. By days 30 and 60 p.i. all animals"/>
 <result pre="all panels, animals exposed to DENV 12 months before ZIKV" exact="infection" post="are in blue, while animals exposed to DENV 3"/>
 <result pre="(B) Average RNAemia days were calculated using the following formula:" exact="total" post="viremia days divided by total possible viremia days and"/>
 <result pre="calculated using the following formula: total viremia days divided by" exact="total" post="possible viremia days and are expressed as percentage. The"/>
 <result pre="consistent in all groups during the first 4 days post" exact="infection" post="(p.i.). Peak viremia occurred on day 3 p.i. Cohort"/>
 <result pre="Days 1 2 3 4 5 6 7 30 60" exact="Total" post="Mean BS97 1° DENV-2 12 months 5.742 (&amp;lt;20) 6.298"/>
 <result pre="6 p.i. (S3 Fig). These results suggest that a previous" exact="infection" post="with DENV contributes to an earlier and significant control"/>
 <result pre="Serological profile is modified by the time between the two" exact="infections" post="To assess the impact of previous exposure to DENV"/>
 <result pre="the cutoff value during the three collection periods, suggesting ZIKV" exact="infection" post="did not induce DENV-specific IgM response (S4A Fig). As"/>
 <result pre="slowly decreasing by day 60 p.i. (S4B Fig). After a" exact="limited" post="increase of the anti-DENV IgG levels on day 30"/>
 <result pre="all ZIKV-infected animals developed anti-ZIKV IgM 30 days after the" exact="infection" post="(S4C Fig). However, those Abs were early detected only"/>
 <result pre="against ZIKV EDIII epitopes and that these Abs may have" exact="limited" post="contribution to ZIKV neutralization. The time between DENV/ZIKV infections"/>
 <result pre="have limited contribution to ZIKV neutralization. The time between DENV/ZIKV" exact="infections" post="modifies the neutralizing profile To determine the contribution of"/>
 <result pre="to the neutralization and the impact of a previous DENV" exact="infection" post="in a subsequent ZIKV infection in terms of neutralization"/>
 <result pre="impact of a previous DENV infection in a subsequent ZIKV" exact="infection" post="in terms of neutralization potential, all three groups were"/>
 <result pre="baseline (Fig 3A). As early as 6 days after the" exact="infection" post="an increase in the neutralizing activity against ZIKV is"/>
 <result pre="the contribution of the humoral immune response to the early" exact="viral" post="replication we further looked at the dilution:neutralization capacity relation"/>
 <result pre="respectively) p.i. However, the role of those early nAbs limiting" exact="viral" post="replication is debatable when the relationship between RNAemia and"/>
 <result pre="still present for DENV-middle convalescent animals, which suggests that ZIKV" exact="infection" post="induced a boost in cross-neutralizing Abs to DENV and"/>
 <result pre="boost depend on the time elapse between DENV and ZIKV" exact="infection" post="(P = 0.0006 for day 30 p.i. and P"/>
 <result pre="measuring DENV-IgG binding using an ELISA (Fig 4A). Due to" exact="limited" post="amount of serum, only 4 animals from the DENV"/>
 <result pre="make up most of the neutralizing force early during ZIKV" exact="infection" post="regardless of any pre-existing DENV immunity (Fig 4D). Fig"/>
 <result pre="of depleted and control sera from day 7 after ZIKV" exact="infection" post="are shown. (D) ZIKV neutralization titers of depleted and"/>
 <result pre="titers of depleted and control sera from day 7 after" exact="infection" post="are shown. Due to limited amount of serum, only"/>
 <result pre="sera from day 7 after infection are shown. Due to" exact="limited" post="amount of serum, only 4 animals from the DENV-12M"/>
 <result pre="serotypes in all three groups, suggesting that a subsequent ZIKV" exact="infection" post="impact the levels of heterologous DENV-neutralizing Abs (S6B Fig)."/>
 <result pre="heterologous DENV-neutralizing Abs (S6B Fig). Interestingly 30 days after ZIKV" exact="infection" post="there was a non-significant trend to higher neutralizing titers"/>
 <result pre="immune response is boosted by the time length between DENV/ZIKV" exact="infections" post="To assess if a previous DENV infection has an"/>
 <result pre="length between DENV/ZIKV infections To assess if a previous DENV" exact="infection" post="has an impact on the T cell response to"/>
 <result pre="CD4+ T cells from the DENV 12M group before ZIKV" exact="infection" post="is remarkable (Fig 5A, upper panel, left). The frequency"/>
 <result pre="DENV 12M group before ZIKV infection is remarkable (Fig 5A," exact="upper" post="panel, left). The frequency of these cells in this"/>
 <result pre="all panels, animals exposed to DENV 12 months before ZIKV" exact="infection" post="are in blue, while animals exposed to DENV 3"/>
 <result pre="different stimuli before (upper panel) and 30 days after ZIKV" exact="infection" post="(lower panel). (B) Analysis of CD8 T cell response"/>
 <result pre="different stimuli before (upper panel) and 30 days after ZIKV" exact="infection" post="(lower panel). Statistically significant differences among groups were calculated"/>
 <result pre="a significantly higher frequency of CD107a+ cells prior to ZIKV" exact="infection" post="(P&amp;lt;0.0001; mean diff.: -0.8775, CI95%: -1.25 to -0.503) against"/>
 <result pre="-1.25 to -0.503) against the whole DENV antigen (Fig 5A," exact="upper" post="panel, right) while a significant increase in reactivity of"/>
 <result pre="mean diff.: -0.8775, CI95%: -1.251 to -0.5035, respectively) (Fig 5A," exact="lower" post="panel, right). Nothing remarkable was observed in TNFα expressing"/>
 <result pre="DENV immunity impacts the cytokine secretion during a subsequent ZIKV" exact="infection" post="(S8 Fig). Naïve macaques had significantly higher levels of"/>
 <result pre="7 p.i., animals exposed to DENV 12 months before ZIKV" exact="infection" post="had a consistently higher expression of IFNγ compared to"/>
 <result pre="result supports a role for this cytolytic protein in early" exact="viral" post="clearance. Other immune cell subsets frequency is shaped by"/>
 <result pre="higher frequency of B cells (CD20+) 24 hours before ZIKV" exact="infection" post="compared to the other groups (P&amp;lt;0.05; mean diff.: -12.33,"/>
 <result pre="dendritic cells. Percentage of plasmacytoid lineage dendritic cells out of" exact="total" post="gated PBMCs. Naïve animals are depicted in black. Animals"/>
 <result pre="in black. Animals exposed to DENV 12 months before ZIKV" exact="infection" post="are in blue, while animals exposed to DENV 3"/>
 <result pre="well established that exposure to DENV prior to a ZIKV" exact="infection" post="results in a qualitative modification of the humoral and"/>
 <result pre="and humans [26, 34–37]. However, we know from sequential DENV" exact="infections" post="in humans that the timing between flavivirus exposure can"/>
 <result pre="it is difficult to establish the exact time of an" exact="infection" post="and more difficult to exactly define the time between"/>
 <result pre="robust model to study the immunological profile after sequential flavivirus" exact="infections" post="[26, 28, 42]. Using the macaque model allows among"/>
 <result pre="model allows among other factors, to normalize the quantity of" exact="viral" post="inoculum, the age and sex of the animals exposed,"/>
 <result pre="the infection. Controlling the timing of exposure between heterologous flavivirus" exact="infections" post="allows for the measurement of the impact of time"/>
 <result pre="impact of the duration of exposure between natural heterologous flavivirus" exact="infections" post="in endemic areas but also provide a model to"/>
 <result pre="for vaccine candidates. Previously we have shown that a DENV" exact="infection" post="2.8 years (late convalescence period) prior to ZIKV exposure"/>
 <result pre="trends toward the control of ZIKV viremia and the decrease" exact="of liver" post="enzymes after infection. Differences were also observed in B-cell"/>
 <result pre="for viremia, suggesting that the length of time after DENV" exact="infection" post="significantly impacts ZIKV replication and most likely its pathogenic"/>
 <result pre="potential role of the length of time elapsed between two" exact="infections" post="in the probability to have symptomatic ZIKV infections. Results"/>
 <result pre="time elapsed between two infections in the probability to have" exact="symptomatic" post="ZIKV infections. Results from a Nicaraguan pediatric cohort showed"/>
 <result pre="showed that when adjusted for age, sex, and recent DENV" exact="infection" post="(defined as 1–2 years before ZIKV infection, similar to"/>
 <result pre="immune group) was significantly associated with a decreased risk of" exact="symptomatic" post="ZIKV infection. In addition, the same work showed that"/>
 <result pre="addition, the same work showed that prior or recent DENV" exact="infection" post="did not affect the rate of total ZIKV infections"/>
 <result pre="or recent DENV infection did not affect the rate of" exact="total" post="ZIKV infections [29]. Additionally, another work carried out at"/>
 <result pre="DENV infection did not affect the rate of total ZIKV" exact="infections" post="[29]. Additionally, another work carried out at Pau da"/>
 <result pre="against DENV NS1 were positively associated with risk of ZIKV" exact="infection" post="but at the same time the presence of IgG1"/>
 <result pre="was associated to a decrease in the probability of ZIKV" exact="infection" post="[30]. This is highly relevant to our results because"/>
 <result pre="results because IgG3 subclass have been associated to recent DENV" exact="infection" post="and are detectable only up to 4 to 6"/>
 <result pre="and the ZIKV RNAemia within the first week of ZIKV" exact="infection" post="that otherwise would be difficult to conduct in human"/>
 <result pre="in human cohorts. From days 5 to 7 after ZIKV" exact="infection" post="we identified a limited increase in the magnitude of"/>
 <result pre="days 5 to 7 after ZIKV infection we identified a" exact="limited" post="increase in the magnitude of ZIKV neutralization activity in"/>
 <result pre="an early expansion of the plasmablast response 6 days after" exact="secondary" post="DENV [44, 45] and primary ZIKV infections [46]. While"/>
 <result pre="plasmablast response 6 days after secondary DENV [44, 45] and" exact="primary" post="ZIKV infections [46]. While no correlation can be made"/>
 <result pre="6 days after secondary DENV [44, 45] and primary ZIKV" exact="infections" post="[46]. While no correlation can be made with the"/>
 <result pre="a consistent increase in the ZIKV nAbs correlating with the" exact="absence of" post="RNAemia was observed only in the animals of DENV"/>
 <result pre="no role controlling ZIKV replication during the first week after" exact="infection" post="and a contribution in limiting ZIKV pathogenesis and clinical"/>
 <result pre="replication contrast the findings from our group in a reverse" exact="infection" post="scenario, suggesting that low-to-intermediary levels of cross-neutralizing Abs against"/>
 <result pre="of cross-neutralizing Abs against DENV induced by a previous ZIKV" exact="infection" post="may play a role in controlling early DENV RNAemia"/>
 <result pre="we can conclude that the neutralization against ZIKV is very" exact="limited" post="or absent in DENV-immune samples, regardless of the convalescence"/>
 <result pre="is known that memory B cells are implicated during a" exact="secondary" post="infection in a DENV-ZIKV scenario, still it is unknown"/>
 <result pre="known that memory B cells are implicated during a secondary" exact="infection" post="in a DENV-ZIKV scenario, still it is unknown how"/>
 <result pre="cells may depend on the length of time passed between" exact="infections" post="[34]. Here, using an accurate depiction of time elapsed"/>
 <result pre="NHP model, we show that the length of time between" exact="infections" post="does impact the quality of this memory recall. It"/>
 <result pre="quality of this memory recall. It is well documented that" exact="secondary" post="flavivirus infections, including ZIKV, lead to an increase in"/>
 <result pre="[32, 34, 48, 49]. Consistent with that, we found a" exact="transient" post="but significant expansion in the magnitude of DENV2 cross-reactive"/>
 <result pre="cross-reactive Abs in the pre-immune groups 30 days after ZIKV" exact="infection" post="with a rapid decline similar to baseline levels by"/>
 <result pre="compared to their baseline values. These results confirm that ZIKV" exact="infection" post="contributes to a transient expansion of DENV neutralization which"/>
 <result pre="values. These results confirm that ZIKV infection contributes to a" exact="transient" post="expansion of DENV neutralization which may play a role"/>
 <result pre="play a role modifying the course of a subsequent DENV" exact="infection" post="in a DENV endemic region. Interestingly, the magnitude of"/>
 <result pre="our previous work showing that time between ZIKV and DENV" exact="infection" post="significantly modify the magnitude of neutralization to the other"/>
 <result pre="that different immune mechanisms are triggered when the sequence of" exact="infections" post="are different [47]. By depleting DENV2 specific Abs from"/>
 <result pre="the same regardless of the time elapsed between the two" exact="infections" post="(being 3 or 12 months). In addition our results"/>
 <result pre="expansion and durability of the DENV nAbs induced by a" exact="secondary" post="ZIKV infection is modest compared to the reported response"/>
 <result pre="durability of the DENV nAbs induced by a secondary ZIKV" exact="infection" post="is modest compared to the reported response induced after"/>
 <result pre="is modest compared to the reported response induced after a" exact="secondary" post="heterologous DENV infection [52, 53]. From our work, we"/>
 <result pre="to the reported response induced after a secondary heterologous DENV" exact="infection" post="[52, 53]. From our work, we can infer a"/>
 <result pre="of the CD4+ T cells present 12 months after DENV" exact="infection" post="and during heterologous ZIKV challenge correlates with better performance"/>
 <result pre="(3 months) or late (2.8 years) [26] convalescence periods after" exact="primary" post="DENV infection. The role of CD4+T cells in flavivirus"/>
 <result pre="primary DENV infection. The role of CD4+T cells in flavivirus" exact="infection" post="has been extensively documented [54, 55]. Importantly, Weiskopf et"/>
 <result pre="DENV-specific CD107a+ CD4+ T correlate with enhanced protection against DENV" exact="disease" post="[56, 57] and play a key role in controlling"/>
 <result pre="disease [56, 57] and play a key role in controlling" exact="secondary" post="flavivirus infections [35]. Our work builds on these observations"/>
 <result pre="57] and play a key role in controlling secondary flavivirus" exact="infections" post="[35]. Our work builds on these observations and demonstrates"/>
 <result pre="DENV specific CD4+ T cells isolated one year after DENV" exact="infection" post="were highly responsive to the whole DENV virus prior"/>
 <result pre="highly responsive to the whole DENV virus prior to ZIKV" exact="infection" post="(characterized by a significantly higher frequency of IFN-γ production"/>
 <result pre="the other two groups. In fact, after 30 days of" exact="infection" post="the focus of CD4+ T cells reactivity was ZIKV"/>
 <result pre="cells are associated with subclinical manifestations in children suffering from" exact="secondary" post="DENV infection [58]. Notably, the data for CD8+T cells"/>
 <result pre="associated with subclinical manifestations in children suffering from secondary DENV" exact="infection" post="[58]. Notably, the data for CD8+T cells did not"/>
 <result pre="cell response changed over time, leading to potential differences in" exact="disease" post="outcome. The significant role of T cells in controlling"/>
 <result pre="replication in animals with a DENV-middle convalescence period before ZIKV" exact="infection" post="is reinforced by the significant increase of circulating cytolytic"/>
 <result pre="peak in perforin levels in serum 6 days after ZIKV" exact="infection" post="in animals with 2.8 years of previous immunity to"/>
 <result pre="CD8+ T cells peaked between 7 and 10 days post-ZIKV" exact="infection" post="[61]. The protective role of the cellular immune response"/>
 <result pre="The protective role of the cellular immune response controlling the" exact="viral" post="burden of ZIKV in mice has been reported [62,"/>
 <result pre="have shown that prior DENV immunity can protect against ZIKV" exact="infection" post="during pregnancy, and CD8+ T cells are sufficient for"/>
 <result pre="in pDCs in patients with more serious forms of DENV" exact="disease" post="such as Dengue Hemorrhagic Fever (DHF) in comparison with"/>
 <result pre="patients with more serious forms of DENV disease such as" exact="Dengue" post="Hemorrhagic Fever (DHF) in comparison with normal DENV or"/>
 <result pre="with more serious forms of DENV disease such as Dengue" exact="Hemorrhagic" post="Fever (DHF) in comparison with normal DENV or healthy"/>
 <result pre="more serious forms of DENV disease such as Dengue Hemorrhagic" exact="Fever" post="(DHF) in comparison with normal DENV or healthy patients"/>
 <result pre="and colleagues reported that higher levels of pDCs correlate with" exact="lower" post="DENV viremia levels [67]. Other viral infections, like HIV-1"/>
 <result pre="of pDCs correlate with lower DENV viremia levels [67]. Other" exact="viral" post="infections, like HIV-1 and HCV, lead to an increase"/>
 <result pre="in long-term survivors, while a decrease has been documented in" exact="chronic" post="patients, accompanied by impairment of cytokine-secreting and T cell-activating"/>
 <result pre="and T cell-activating capacities of pDCs. In addition, during influenza" exact="infection" post="pDCs are capable of priming primary and secondary CD4"/>
 <result pre="In addition, during influenza infection pDCs are capable of priming" exact="primary" post="and secondary CD4 and CD8 T cell responses in"/>
 <result pre="during influenza infection pDCs are capable of priming primary and" exact="secondary" post="CD4 and CD8 T cell responses in vitro and"/>
 <result pre="and IFN β, activating innate and adaptive immune responses during" exact="viral" post="infections [69, 71, 72]. Virus-stimulated pDCs are responsible for"/>
 <result pre="IFN β, activating innate and adaptive immune responses during viral" exact="infections" post="[69, 71, 72]. Virus-stimulated pDCs are responsible for a"/>
 <result pre="T cells [69]. Thus, their recruitment to lymphoid and some" exact="peripheral" post="tissues leads to an ongoing inflammatory response and the"/>
 <result pre="the activation of the adaptive response against DENV and ZIKV" exact="infections" post="involves signals and interactions from pDCs and T cells."/>
 <result pre="of the protective immune response. We present evidences supporting a" exact="limited" post="role, if any, of the pre-existing DENV humoral immune"/>
 <result pre="previous DENV immunity or the time between DENV and ZIKV" exact="infections" post="may have any implications during pregnancy. However, studies addressing"/>
 <result pre="to an increase of fetal damage [73, 74]. Moreover, the" exact="Brazilian" post="study concluded that multitypic DENV infections may protect, rather"/>
 <result pre="[73, 74]. Moreover, the Brazilian study concluded that multitypic DENV" exact="infections" post="may protect, rather than enhance, from development of CZS."/>
 <result pre="between the more recent DENV epidemics in Brazil and the" exact="microcephaly" post="epidemic observed after the introduction of ZIKV was in"/>
 <result pre="it is possible to argue that the sequence of ZIKV-DENV" exact="infections" post="[47] induces a different immunological response—in terms of the"/>
 <result pre="shown here. However, in both scenarios, the time interval between" exact="infections" post="seems to play a critical role in the quality"/>
 <result pre="of ZIKV and DENV vaccine schedules, design and monitoring. Methods" exact="Viral" post="stock ZIKV PRVABC59 strain was obtained from ATCC, BEI"/>
 <result pre="ZIKV strain replicates well in rhesus macaques but has a" exact="lower" post="viremia peak than ZIKV H/PF/2013 strain. We aimed to"/>
 <result pre="Animal Research Center and evaluated twice daily for evidence of" exact="disease" post="or injury. Feeding and drinking continued normally during this"/>
 <result pre="by the IACUC. Immunization and virus challenge of macaques Young" exact="adult" post="rhesus macaques (4–7 years of age) seronegative for DENV"/>
 <result pre="taken on Day 0 and every other day during the" exact="acute" post="infection period (days 1–6, then at day 30 p.i.)."/>
 <result pre="on Day 0 and every other day during the acute" exact="infection" post="period (days 1–6, then at day 30 p.i.). Rectal"/>
 <result pre="day 30 p.i.). Rectal temperature was taken daily during the" exact="acute" post="infection period (days 1–6 and on day 30 p.i.)."/>
 <result pre="30 p.i.). Rectal temperature was taken daily during the acute" exact="infection" post="period (days 1–6 and on day 30 p.i.). Note"/>
 <result pre="well plates with growth medium (Dulbecco’s Modified Eagle’s medium, Thermo" exact="Fisher" post="Scientific, with 10% FBS (Gibco), 1% non-essential amino acids"/>
 <result pre="(Gibco), 1% antibiotic/antimycotic (HyClone)) was added to the plates containing" exact="viral" post="dilutions, followed by an incubation period at 37C/5%CO2. After"/>
 <result pre="greater, while &amp;lt;1:20 was considered a negative neutralization titer. qRT-PCR" exact="Viral" post="RNA for real-time PCR assay was extracted from 140"/>
 <result pre="developed by the Molecular Diagnostics and Research Laboratory Centers for" exact="Disease" post="Control and Prevention (CDC), Dengue Branch at San Juan,"/>
 <result pre="and Research Laboratory Centers for Disease Control and Prevention (CDC)," exact="Dengue" post="Branch at San Juan, PR. RNA from other flaviviruses"/>
 <result pre="mM primers and 25 mM probe in a 25 ml" exact="total" post="volume using Life Technologies SuperScriptIII Platinum assay kit (Life"/>
 <result pre="Results were expressed as mean OD of sample reacted with" exact="viral" post="antigen (P)/mean OD of normal human serum reacted with"/>
 <result pre="viral antigen (P)/mean OD of normal human serum reacted with" exact="viral" post="antigen (N) and reported as negative (P/N value of"/>
 <result pre="(1:40 100 ul/well) and IgG-binding Abs were detected using AP-conjugated" exact="secondary" post="anti-goat Ab (1:2500). Absorbance was measured at 405 nm."/>
 <result pre="Prism 7.0 software (GraphPad Software, San Diego, CA, USA). For" exact="viral" post="burden analysis, the log titers and levels of vRNA"/>
 <result pre="was measured. Animals exposed to DENV 12 months before ZIKV" exact="infection" post="are depicted in blue, while animals exposed to DENV"/>
 <result pre="Kinetics of hematology and laboratory results. Cell subsets obtained from" exact="complete" post="blood count (CBC) tests at baseline, 6 and 30"/>
 <result pre="all panels, animals exposed to DENV 12 months before ZIKV" exact="infection" post="are in blue, while animals exposed to DENV 3"/>
 <result pre="Naïve animals are in black. (A) White blood cells (WBC)" exact="total" post="depicted in thou/uL. (B) Platelet (PLT) levels total depicted"/>
 <result pre="(A) White blood cells (WBC) total depicted in thou/uL. (B)" exact="Platelet" post="(PLT) levels total depicted in thou/uL. (C) Monocyte (MON)"/>
 <result pre="cells (WBC) total depicted in thou/uL. (B) Platelet (PLT) levels" exact="total" post="depicted in thou/uL. (C) Monocyte (MON) kinetics expressed as"/>
 <result pre="thou/uL. (B) Platelet (PLT) levels total depicted in thou/uL. (C)" exact="Monocyte" post="(MON) kinetics expressed as absolute numbers (x10^6 cells/mL). Statistically"/>
 <result pre="6 p.i. Animals exposed to DENV 12 months before ZIKV" exact="infection" post="are in blue, while animals exposed 3 months before"/>
 <result pre="all panels, animals exposed to DENV 12 months before ZIKV" exact="infection" post="are in blue, while animals exposed to DENV 3"/>
 <result pre="all panels, animals exposed to DENV 12 months before ZIKV" exact="infection" post="are in blue, while animals exposed to DENV 3"/>
 <result pre="all panels, animals exposed to DENV 12 months before ZIKV" exact="infection" post="are in blue, while animals exposed to DENV 3"/>
 <result pre="in orange. Naïve animals are in black. (A) Percentage of" exact="total" post="B cells (CD20+) during baseline and days 1 through"/>
 <result pre="dendritic cells. Percentage of myeloid lineage dendritic cells out of" exact="total" post="gated PBMCs. Animals exposed to DENV 12 months before"/>
 <result pre="gated PBMCs. Animals exposed to DENV 12 months before ZIKV" exact="infection" post="are colored blue, while animals exposed 3 months before"/>
 <result pre="the immunology data. References References 1CamposGC, SardiSI, SarnoM, BritesC. Zika" exact="virus infection," post="a new public health challenge. The Brazilian journal of"/>
 <result pre="BritesC. Zika virus infection, a new public health challenge. The" exact="Brazilian" post="journal of infectious diseases: an official publication of the"/>
 <result pre="infection, a new public health challenge. The Brazilian journal of" exact="infectious" post="diseases: an official publication of the Brazilian Society of"/>
 <result pre="Brazilian journal of infectious diseases: an official publication of the" exact="Brazilian" post="Society of Infectious Diseases. 2016;20(3):227–8. 10.1016/j.bjid.2016.05.001 .27215946 2BrasilP, PereiraJPJr.,"/>
 <result pre="infectious diseases: an official publication of the Brazilian Society of" exact="Infectious" post="Diseases. 2016;20(3):227–8. 10.1016/j.bjid.2016.05.001 .27215946 2BrasilP, PereiraJPJr., MoreiraME, Ribeiro NogueiraRM,"/>
 <result pre="2BrasilP, PereiraJPJr., MoreiraME, Ribeiro NogueiraRM, DamascenoL, WakimotoM, et al.Zika Virus" exact="Infection" post="in Pregnant Women in Rio de Janeiro. The New"/>
 <result pre="10.1056/NEJMoa1602412 .26943629 3Cao-LomeauVM, BlakeA, MonsS, LastereS, RocheC, VanhomwegenJ, et al.Guillain-Barre" exact="Syndrome" post="outbreak associated with Zika virus infection in French Polynesia:"/>
 <result pre="LastereS, RocheC, VanhomwegenJ, et al.Guillain-Barre Syndrome outbreak associated with Zika" exact="virus infection" post="in French Polynesia: a case-control study. Lancet. 2016; 10.1016/S0140-6736(16)00562-6"/>
 <result pre="RocheC, VanhomwegenJ, et al.Guillain-Barre Syndrome outbreak associated with Zika virus" exact="infection" post="in French Polynesia: a case-control study. Lancet. 2016; 10.1016/S0140-6736(16)00562-6"/>
 <result pre="Euro surveillance: bulletin Europeen sur les maladies transmissibles = European" exact="communicable disease" post="bulletin. 2016;21(16): 10.2807/1560-7917.ES.2016.21.16.30205 .27123558 5CarteauxG, MaquartM, BedetA, ContouD, BrugieresP,"/>
 <result pre="surveillance: bulletin Europeen sur les maladies transmissibles = European communicable" exact="disease" post="bulletin. 2016;21(16): 10.2807/1560-7917.ES.2016.21.16.30205 .27123558 5CarteauxG, MaquartM, BedetA, ContouD, BrugieresP,"/>
 <result pre="10.1056/NEJMc1602964 .26958738 6MecharlesS, HerrmannC, PoullainP, TranTH, DeschampsN, MathonG, et al.Acute" exact="myelitis" post="due to Zika virus infection. Lancet. 2016;387(10026):148110.1016/S0140-6736(16)00644-9 .26946926 7FurtadoJM,"/>
 <result pre="PoullainP, TranTH, DeschampsN, MathonG, et al.Acute myelitis due to Zika" exact="virus infection." post="Lancet. 2016;387(10026):148110.1016/S0140-6736(16)00644-9 .26946926 7FurtadoJM, EspositoDL, KleinTM, Teixeira-PintoT, da FonsecaBA."/>
 <result pre="infection. Lancet. 2016;387(10026):148110.1016/S0140-6736(16)00644-9 .26946926 7FurtadoJM, EspositoDL, KleinTM, Teixeira-PintoT, da FonsecaBA." exact="Uveitis" post="Associated with Zika Virus Infection. The New England journal"/>
 <result pre=".27332784 8SharpTM, Munoz-JordanJ, Perez-PadillaJ, Bello-PaganMI, RiveraA, PastulaDM, et al.Zika Virus" exact="Infection" post="Associated With Severe Thrombocytopenia. Clinical infectious diseases: an official"/>
 <result pre="Perez-PadillaJ, Bello-PaganMI, RiveraA, PastulaDM, et al.Zika Virus Infection Associated With" exact="Severe" post="Thrombocytopenia. Clinical infectious diseases: an official publication of the"/>
 <result pre="PastulaDM, et al.Zika Virus Infection Associated With Severe Thrombocytopenia. Clinical" exact="infectious" post="diseases: an official publication of the Infectious Diseases Society"/>
 <result pre="Severe Thrombocytopenia. Clinical infectious diseases: an official publication of the" exact="Infectious" post="Diseases Society of America. 2016; Epub 2016/07/16. 10.1093/cid/ciw476 .27418575"/>
 <result pre="Thrombocytopenia. Clinical infectious diseases: an official publication of the Infectious" exact="Diseases" post="Society of America. 2016; Epub 2016/07/16. 10.1093/cid/ciw476 .27418575 9D’OrtenzioE,"/>
 <result pre="NhanT, TeissierA, Cao-LormeauVM. Potential sexual transmission of Zika virus. Emerging" exact="infectious diseases." post="2015;21(2):359–61. Epub 2015/01/28. 10.3201/eid2102.141363 .25625872 11RussellK, HillsSL, OsterAM, PorseCC,"/>
 <result pre="al.Male-to-Female Sexual Transmission of Zika Virus-United States, January-April 2016. Clinical" exact="infectious" post="diseases: an official publication of the Infectious Diseases Society"/>
 <result pre="January-April 2016. Clinical infectious diseases: an official publication of the" exact="Infectious" post="Diseases Society of America. 2017;64(2):211–3. Epub 2016/12/18. 10.1093/cid/ciw692 .27986688"/>
 <result pre="2016. Clinical infectious diseases: an official publication of the Infectious" exact="Diseases" post="Society of America. 2017;64(2):211–3. Epub 2016/12/18. 10.1093/cid/ciw692 .27986688 12CostaF,"/>
 <result pre="SarnoM, KhouriR, de Paula FreitasB, SiqueiraI, RibeiroGS, et al.Emergence of" exact="Congenital" post="Zika Syndrome: Viewpoint From the Front Lines. Annals of"/>
 <result pre="SantosCM, AlmeidaLC, Van Der LindenV, et al.Hearing Loss in Infants" exact="with Microcephaly" post="and Evidence of Congenital Zika Virus Infection—Brazil, November 2015-May"/>
 <result pre="AlmeidaLC, Van Der LindenV, et al.Hearing Loss in Infants with" exact="Microcephaly" post="and Evidence of Congenital Zika Virus Infection—Brazil, November 2015-May"/>
 <result pre="et al.Hearing Loss in Infants with Microcephaly and Evidence of" exact="Congenital" post="Zika Virus Infection—Brazil, November 2015-May 2016. MMWR Morbidity and"/>
 <result pre="10.15585/mmwr.mm6534e3 .27585248 14TeixeiraMG, Costa MdaC, de OliveiraWK, NunesML, RodriguesLC. The" exact="Epidemic" post="of Zika Virus-Related Microcephaly in Brazil: Detection, Control, Etiology,"/>
 <result pre="MdaC, de OliveiraWK, NunesML, RodriguesLC. The Epidemic of Zika Virus-Related" exact="Microcephaly" post="in Brazil: Detection, Control, Etiology, and Future Scenarios. American"/>
 <result pre="Virus-Related Microcephaly in Brazil: Detection, Control, Etiology, and Future Scenarios." exact="American" post="journal of public health. 2016;106(4):601–5. Epub 2016/03/10. 10.2105/AJPH.2016.303113 .26959259"/>
 <result pre="2016/03/10. 10.2105/AJPH.2016.303113 .26959259 15Rodriguez-MoralesAJ, Villamil-GomezWE, Franco-ParedesC. The arboviral burden of" exact="disease" post="caused by co-circulation and co-infection of dengue, chikungunya and"/>
 <result pre="burden of disease caused by co-circulation and co-infection of dengue," exact="chikungunya" post="and Zika in the Americas. Travel medicine and infectious"/>
 <result pre="dengue, chikungunya and Zika in the Americas. Travel medicine and" exact="infectious disease." post="2016;14(3):177–9. Epub 2016/05/26. 10.1016/j.tmaid.2016.05.004 .27224471 16LesslerJ, ChaissonLH, KucirkaLM, BiQ,"/>
 <result pre="York, NY). 2016;353(6300):aaf8160 Epub 2016/07/16. 10.1126/science.aaf8160 .27417495 17GuzmanMG, AlvarezM, HalsteadSB." exact="Secondary" post="infection as a risk factor for dengue hemorrhagic fever/dengue"/>
 <result pre="NY). 2016;353(6300):aaf8160 Epub 2016/07/16. 10.1126/science.aaf8160 .27417495 17GuzmanMG, AlvarezM, HalsteadSB. Secondary" exact="infection" post="as a risk factor for dengue hemorrhagic fever/dengue shock"/>
 <result pre="et al.A shorter time interval between first and second dengue" exact="infections" post="is associated with protection from clinical illness in a"/>
 <result pre="illness in a school-based cohort in Thailand. The Journal of" exact="infectious diseases." post="2014;209(3):360–8. Epub 2013/08/22. 10.1093/infdis/jit436 .23964110 19GuzmanMG, KouriG, ValdesL, BravoJ,"/>
 <result pre=".23964110 19GuzmanMG, KouriG, ValdesL, BravoJ, VazquezS, HalsteadSB. Enhanced severity of" exact="secondary" post="dengue-2 infections: death rates in 1981 and 1997 Cuban"/>
 <result pre="GutierrezG, et al.Symptomatic versus inapparent outcome in repeat dengue virus" exact="infections" post="is influenced by the time interval between infections and"/>
 <result pre="dengue virus infections is influenced by the time interval between" exact="infections" post="and study year. PLoS neglected tropical diseases. 2013;7(8):e2357 Epub"/>
 <result pre="that maternal dengue antibodies are important in the development of" exact="dengue hemorrhagic fever" post="in infants. The American journal of tropical medicine and"/>
 <result pre="in the development of dengue hemorrhagic fever in infants. The" exact="American" post="journal of tropical medicine and hygiene. 1988;38(2):411–9. Epub 1988/03/01."/>
 <result pre="al.Dengue in Vietnamese infants—results of infection-enhancement assays correlate with age-related" exact="disease" post="epidemiology, and cellular immune responses correlate with disease severity."/>
 <result pre="with age-related disease epidemiology, and cellular immune responses correlate with" exact="disease" post="severity. The Journal of infectious diseases. 2008;198(4):516–24. Epub 2008/07/05."/>
 <result pre="cellular immune responses correlate with disease severity. The Journal of" exact="infectious diseases." post="2008;198(4):516–24. Epub 2008/07/05. 10.1086/590117 .18598189 23MongkolsapayaJ, DuangchindaT, DejnirattisaiW, VasanawathanaS,"/>
 <result pre="an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with" exact="disease" post="severity. J Immunol. 2002;168(11):5959–65. 10.4049/jimmunol.168.11.5959 .12023403 25MongkolsapayaJ, DejnirattisaiW, XuXN,"/>
 <result pre="et al.Original antigenic sin and apoptosis in the pathogenesis of" exact="dengue hemorrhagic fever." post="Nature medicine. 2003;9(7):921–7. Epub 2003/06/17. 10.1038/nm887 .12808447 26PantojaP, Perez-GuzmanEX,"/>
 <result pre="10.1038/ncomms15674 .28643775 27BreitbachME, NewmanCM, DudleyDM, StewartLM, AliotaMT, KoenigMR, et al.Primary" exact="infection" post="with dengue or Zika virus does not affect the"/>
 <result pre="or Zika virus does not affect the severity of heterologous" exact="secondary" post="infection in macaques. PLoS Pathog. 2019;15(8):e1007766 Epub 2019/08/02. 10.1371/journal.ppat.1007766"/>
 <result pre="Zika virus does not affect the severity of heterologous secondary" exact="infection" post="in macaques. PLoS Pathog. 2019;15(8):e1007766 Epub 2019/08/02. 10.1371/journal.ppat.1007766 following"/>
 <result pre="La BarreraR, et al.Impact of prior flavivirus immunity on Zika" exact="virus infection" post="in rhesus macaques. PLoS pathogens. 2017;13(8):e100648710.1371/journal.ppat.1006487 .28771605 29GordonA, GreshL,"/>
 <result pre="BarreraR, et al.Impact of prior flavivirus immunity on Zika virus" exact="infection" post="in rhesus macaques. PLoS pathogens. 2017;13(8):e100648710.1371/journal.ppat.1006487 .28771605 29GordonA, GreshL,"/>
 <result pre=".28771605 29GordonA, GreshL, OjedaS, KatzelnickLC, SanchezN, MercadoJC, et al.Prior dengue" exact="virus infection" post="and risk of Zika: A pediatric cohort in Nicaragua."/>
 <result pre="29GordonA, GreshL, OjedaS, KatzelnickLC, SanchezN, MercadoJC, et al.Prior dengue virus" exact="infection" post="and risk of Zika: A pediatric cohort in Nicaragua."/>
 <result pre="et al.Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from" exact="Dengue" post="Virus Infection. Emerging infectious diseases. 2017;23(5):773–81. 10.3201/eid2305.161630 .28418292 33EstesJD,"/>
 <result pre="Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection. Emerging" exact="infectious diseases." post="2017;23(5):773–81. 10.3201/eid2305.161630 .28418292 33EstesJD, WongSW, BrenchleyJM. Nonhuman primate models"/>
 <result pre="10.3201/eid2305.161630 .28418292 33EstesJD, WongSW, BrenchleyJM. Nonhuman primate models of human" exact="viral" post="infections. Nature reviews Immunology. 2018;18(6):390–404. Epub 2018/03/21. 10.1038/s41577-018-0005-7 .29556017"/>
 <result pre="34PriyamvadaL, SutharMS, AhmedR, WrammertJ. Humoral Immune Responses Against Zika Virus" exact="Infection" post="and the Importance of Preexisting Flavivirus Immunity. The Journal"/>
 <result pre="and the Importance of Preexisting Flavivirus Immunity. The Journal of" exact="infectious diseases." post="2017;216(suppl_10):S906–s11. Epub 2017/12/22. 10.1093/infdis/jix513 .29267924 35GrifoniA, PhamJ, SidneyJ, O’RourkePH,"/>
 <result pre="10.1093/infdis/jix513 .29267924 35GrifoniA, PhamJ, SidneyJ, O’RourkePH, PaulS, PetersB, et al.Prior" exact="Dengue" post="virus exposure shapes T cell immunity to Zika virus"/>
 <result pre="Zika Virus Infection, Immunity, and Therapeutic Development. The Journal of" exact="infectious diseases." post="2017;216(suppl_10):S928–s34. Epub 2017/12/22. 10.1093/infdis/jix540 .29267926 37WenJ, ShrestaS. T Cell"/>
 <result pre="10.1093/infdis/jix540 .29267926 37WenJ, ShrestaS. T Cell Immunity to Zika and" exact="Dengue" post="Viral Infections. Journal of interferon &amp;amp; cytokine research: the"/>
 <result pre=".29267926 37WenJ, ShrestaS. T Cell Immunity to Zika and Dengue" exact="Viral" post="Infections. Journal of interferon &amp;amp; cytokine research: the official"/>
 <result pre="design, methods, use of information technology, and extension to other" exact="infectious diseases." post="American journal of epidemiology. 2009;170(1):120–9. Epub 2009/05/14. 10.1093/aje/kwp092 .19435864"/>
 <result pre="use of information technology, and extension to other infectious diseases." exact="American" post="journal of epidemiology. 2009;170(1):120–9. Epub 2009/05/14. 10.1093/aje/kwp092 .19435864 39GordonA,"/>
 <result pre="al.The Nicaraguan pediatric dengue cohort study: incidence of inapparent and" exact="symptomatic" post="dengue virus infections, 2004–2010. PLoS neglected tropical diseases. 2013;7(9):e2462"/>
 <result pre="al.Longitudinal Analysis of Memory B and T Cell Responses to" exact="Dengue" post="Virus in a 5-Year Prospective Cohort Study in Thailand."/>
 <result pre="in Nicaraguan Patients Infected With Zika Virus, Chikungunya Virus, and" exact="Dengue" post="Virus. Clinical infectious diseases: an official publication of the"/>
 <result pre="Infected With Zika Virus, Chikungunya Virus, and Dengue Virus. Clinical" exact="infectious" post="diseases: an official publication of the Infectious Diseases Society"/>
 <result pre="Dengue Virus. Clinical infectious diseases: an official publication of the" exact="Infectious" post="Diseases Society of America. 2016;63(12):1584–90. Epub 2016/09/01. 10.1093/cid/ciw589 .27578819"/>
 <result pre="Virus. Clinical infectious diseases: an official publication of the Infectious" exact="Diseases" post="Society of America. 2016;63(12):1584–90. Epub 2016/09/01. 10.1093/cid/ciw589 .27578819 42AliotaMT,"/>
 <result pre="al.Does prior dengue virus exposure worsen clinical outcomes of Zika" exact="virus infection?" post="A systematic review, pooled analysis and lessons learned. PLoS"/>
 <result pre="ChoA, OnlamoonN, ZhengNY, HuangM, KovalenkovY, et al.B Cell Responses during" exact="Secondary" post="Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived"/>
 <result pre="OnlamoonN, ZhengNY, HuangM, KovalenkovY, et al.B Cell Responses during Secondary" exact="Dengue" post="Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts."/>
 <result pre="HuangM, KovalenkovY, et al.B Cell Responses during Secondary Dengue Virus" exact="Infection" post="Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts. Journal of"/>
 <result pre="PolsrilaK, ChandeleA, et al.Rapid and massive virus-specific plasmablast responses during" exact="acute" post="dengue virus infection in humans. Journal of virology. 2012;86(6):2911–8."/>
 <result pre="et al.Rapid and massive virus-specific plasmablast responses during acute dengue" exact="virus infection" post="in humans. Journal of virology. 2012;86(6):2911–8. Epub 2012/01/13. 10.1128/JVI.06075-11"/>
 <result pre="al.Rapid and massive virus-specific plasmablast responses during acute dengue virus" exact="infection" post="in humans. Journal of virology. 2012;86(6):2911–8. Epub 2012/01/13. 10.1128/JVI.06075-11"/>
 <result pre="Serrano-CollazoC, HassertMA, Ortiz-RosaA, RodríguezIV, et al.Time elapsed between Zika and" exact="Dengue" post="infections improves the immune response against Dengue without viremia"/>
 <result pre="HassertMA, Ortiz-RosaA, RodríguezIV, et al.Time elapsed between Zika and Dengue" exact="infections" post="improves the immune response against Dengue without viremia enhancement"/>
 <result pre="between Zika and Dengue infections improves the immune response against" exact="Dengue" post="without viremia enhancement in rhesus macaques. bioRxiv. 2019:621094. 48LanciottiRS,"/>
 <result pre="virus associated with an epidemic, Yap State, Micronesia, 2007. Emerging" exact="infectious diseases." post="2008;14(8):1232–9. Epub 2008/08/06. 10.3201/eid1408.080287 .18680646 49MontoyaM, CollinsM, DejnirattisaiW, KatzelnickLC,"/>
 <result pre="49MontoyaM, CollinsM, DejnirattisaiW, KatzelnickLC, Puerta-GuardoH, JadiR, et al.Longitudinal Analysis of" exact="Antibody" post="Cross-neutralization Following Zika Virus and Dengue Virus Infection in"/>
 <result pre="et al.Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and" exact="Dengue" post="Virus Infection in Asia and the Americas. J Infect"/>
 <result pre="Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus" exact="Infection" post="in Asia and the Americas. J Infect Dis. 2018;218(4):536–45."/>
 <result pre="51LaiL, RouphaelN, XuY, NatrajanMS, BeckA, HartM, et al.Innate, T-, and" exact="B-Cell" post="Responses in Acute Human Zika Patients. Clinical infectious diseases:"/>
 <result pre="NatrajanMS, BeckA, HartM, et al.Innate, T-, and B-Cell Responses in" exact="Acute" post="Human Zika Patients. Clinical infectious diseases: an official publication"/>
 <result pre="T-, and B-Cell Responses in Acute Human Zika Patients. Clinical" exact="infectious" post="diseases: an official publication of the Infectious Diseases Society"/>
 <result pre="Zika Patients. Clinical infectious diseases: an official publication of the" exact="Infectious" post="Diseases Society of America. 2018;66(1):1–10. Epub 2017/10/12. 10.1093/cid/cix732 .29020226"/>
 <result pre="Patients. Clinical infectious diseases: an official publication of the Infectious" exact="Diseases" post="Society of America. 2018;66(1):1–10. Epub 2017/10/12. 10.1093/cid/cix732 .29020226 52PatelB,"/>
 <result pre="HarrisE, de SilvaAM. Dissecting the human serum antibody response to" exact="secondary" post="dengue virus infections. PLoS neglected tropical diseases. 2017;11(5):e0005554 Epub"/>
 <result pre="10.1371/journal.pntd.0005554 .28505154 53WahalaWM, SilvaAM. The human antibody response to dengue" exact="virus infection." post="Viruses. 2011;3(12):2374–95. 10.3390/v3122374 .22355444 54TianY, SetteA, WeiskopfD. Cytotoxic CD4"/>
 <result pre="WeiskopfD. Cytotoxic CD4 T Cells: Differentiation, Function, and Application to" exact="Dengue" post="Virus Infection. Front Immunol. 2016;7:531 Epub 2016/12/23. 10.3389/fimmu.2016.00531 .28003809"/>
 <result pre="BrienJD, PintoAK. CD4+T cells mediate protection against Zika associated severe" exact="disease" post="in a mouse model of infection. PLoS Pathog. 2018;14(9):e1007237"/>
 <result pre="57WeiskopfD, BangsDJ, SidneyJ, KollaRV, De SilvaAD, de SilvaAM, et al.Dengue" exact="virus infection" post="elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated"/>
 <result pre="BangsDJ, SidneyJ, KollaRV, De SilvaAD, de SilvaAM, et al.Dengue virus" exact="infection" post="elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated"/>
 <result pre="cytokine production by dengue virus-specific T cells correlates with subclinical" exact="secondary" post="infection. The Journal of infectious diseases. 2011;203(9):1282–91. Epub 2011/02/22."/>
 <result pre="T cells correlates with subclinical secondary infection. The Journal of" exact="infectious diseases." post="2011;203(9):1282–91. Epub 2011/02/22. 10.1093/infdis/jir012 .21335561 59WilkinsonTM, LiCK, ChuiCS, HuangAK,"/>
 <result pre="PerkinsM, LiebnerJC, et al.Preexisting influenza-specific CD4+ T cells correlate with" exact="disease" post="protection against influenza challenge in humans. Nature medicine. 2012;18(2):274–80."/>
 <result pre="induction of CD4+ T cells with cytotoxic potential during influenza" exact="virus infection." post="Journal of virology. 2013;87(21):11884–93. Epub 2013/08/30. 10.1128/JVI.01461-13 .23986597 61HirschAJ,"/>
 <result pre=".23986597 61HirschAJ, SmithJL, HaeseNN, BroeckelRM, ParkinsCJ, KreklywichC, et al.Zika Virus" exact="infection" post="of rhesus macaques leads to viral persistence in multiple"/>
 <result pre="KreklywichC, et al.Zika Virus infection of rhesus macaques leads to" exact="viral" post="persistence in multiple tissues. PLoS Pathog. 2017;13(3):e1006219 Epub 2017/03/10."/>
 <result pre=".28288094 64Regla-NavaJA, Elong NgonoA, ViramontesKM, HuynhAT, WangYT, NguyenAT, et al.Cross-reactive" exact="Dengue" post="virus-specific CD8(+) T cells protect against Zika virus during"/>
 <result pre="al.Identification of changes in dendritic cell subsets that correlate with" exact="disease" post="severity in dengue infection. PLoS One. 2018;13(7):e0200564 Epub 2018/07/13."/>
 <result pre="et al.A blunted blood plasmacytoid dendritic cell response to an" exact="acute" post="systemic viral infection is associated with increased disease severity."/>
 <result pre="al.A blunted blood plasmacytoid dendritic cell response to an acute" exact="systemic" post="viral infection is associated with increased disease severity. J"/>
 <result pre="blunted blood plasmacytoid dendritic cell response to an acute systemic" exact="viral infection" post="is associated with increased disease severity. J Immunol. 2003;171(10):5571–8."/>
 <result pre="blood plasmacytoid dendritic cell response to an acute systemic viral" exact="infection" post="is associated with increased disease severity. J Immunol. 2003;171(10):5571–8."/>
 <result pre="to an acute systemic viral infection is associated with increased" exact="disease" post="severity. J Immunol. 2003;171(10):5571–8. Epub 2003/11/11. 10.4049/jimmunol.171.10.5571 .14607965 67De"/>
 <result pre="10.4049/jimmunol.171.10.5571 .14607965 67De Carvalho BittencourtM, MartialJ, CabieA, ThomasL, CesaireR. Decreased" exact="peripheral" post="dendritic cell numbers in dengue virus infection. Journal of"/>
 <result pre="CabieA, ThomasL, CesaireR. Decreased peripheral dendritic cell numbers in dengue" exact="virus infection." post="Journal of clinical immunology. 2012;32(1):161–72. Epub 2011/10/05. 10.1007/s10875-011-9592-9 .21969208"/>
 <result pre=".25566258 73PedrosoC, FischerC, FeldmannM, SarnoM, LuzE, Moreira-SotoA, et al.Cross-Protection of" exact="Dengue" post="Virus Infection against Congenital Zika Syndrome, Northeastern Brazil. Emerging"/>
 <result pre="FischerC, FeldmannM, SarnoM, LuzE, Moreira-SotoA, et al.Cross-Protection of Dengue Virus" exact="Infection" post="against Congenital Zika Syndrome, Northeastern Brazil. Emerging infectious diseases."/>
 <result pre="SarnoM, LuzE, Moreira-SotoA, et al.Cross-Protection of Dengue Virus Infection against" exact="Congenital" post="Zika Syndrome, Northeastern Brazil. Emerging infectious diseases. 2019;25(8):1485–93. Epub"/>
 <result pre="Dengue Virus Infection against Congenital Zika Syndrome, Northeastern Brazil. Emerging" exact="infectious diseases." post="2019;25(8):1485–93. Epub 2019/05/11. 10.3201/eid2508.190113 .31075077 74ZavattoniM, RovidaF, PercivalleE, CassanitiI,"/>
 <result pre=".31075077 74ZavattoniM, RovidaF, PercivalleE, CassanitiI, SarasiniA, ArossaA, et al.Zika Virus" exact="Infection" post="in Pregnancy: Advanced Diagnostic Approaches in Dengue-Naive and Dengue-Experienced"/>
 <result pre="PercivalleE, CassanitiI, SarasiniA, ArossaA, et al.Zika Virus Infection in Pregnancy:" exact="Advanced" post="Diagnostic Approaches in Dengue-Naive and Dengue-Experienced Pregnant Women and"/>
 <result pre="10.3390/microorganisms8010056 .31905661 75CarvalhoMS, FreitasLP, CruzOG, BrasilP, BastosLS. Association of past" exact="dengue fever" post="epidemics with the risk of Zika microcephaly at the"/>
 <result pre="of past dengue fever epidemics with the risk of Zika" exact="microcephaly" post="at the population level in Brazil. Sci Rep. 2020;10(1):1752"/>
 <result pre="virus and microcephaly: where do we go from here?The Lancet" exact="Infectious" post="diseases. 2018;18(3):236–7. Epub 2017/12/16. 10.1016/S1473-3099(17)30697-7 .29242092 77RobbianiDF, OlsenPC, CostaF,"/>
 <result pre="77RobbianiDF, OlsenPC, CostaF, WangQ, OliveiraTY, NeryNJr., et al.Risk of Zika" exact="microcephaly" post="correlates with features of maternal antibodies. J Exp Med."/>
</results>
